Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Early Phase 1

Completed

Conditions: Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Erythroleukemia (M6a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: Sirolimus
Drug: Idarubicin
Drug: Cytarabine

First Posted Date: 2013-04-01

Last Posted Date: 2023-02-03

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 55

Registration Number: NCT01822015

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy

Not Applicable

Completed

Conditions: Recurrent Breast Cancer
Ductal Breast Carcinoma in Situ
Invasive Lobular Breast Carcinoma
Lobular Breast Carcinoma in Situ
Invasive Ductal Breast Carcinoma
Stage IB Breast Cancer
Stage IA Breast Cancer

Interventions: Behavioral: Behavioral dietary intervention
Procedure: Therapeutic conventional surgery
Radiation: Radiation therapy
Other: Counseling intervention
Procedure: Quality-of-life assessment

First Posted Date: 2013-03-27

Last Posted Date: 2024-03-13

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 38

Registration Number: NCT01819233

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer

Phase 2

Completed

Conditions: HER2-negative Breast Cancer
Stage II Breast Cancer
Stage IIIC Breast Cancer
Triple-negative Breast Cancer
Estrogen Receptor-negative Breast Cancer
Stage IIIA Breast Cancer
Progesterone Receptor-negative Breast Cancer
Stage IIIB Breast Cancer

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: Doxorubicin
Drug: Cyclophosphamide
Drug: Veliparib

First Posted Date: 2013-03-26

Last Posted Date: 2019-10-28

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 9

Registration Number: NCT01818063

Locations: 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
🇺🇸
Reading Hospital, Reading, Pennsylvania, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies

First Posted Date: 2013-01-04

Last Posted Date: 2023-01-06

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 62

Registration Number: NCT01760655

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

Phase 1

Completed

Conditions: Recurrent Melanoma
Stage IV Melanoma
Tumors Metastatic to Brain

Interventions: Drug: Ipilimumab
Radiation: Stereotactic Radiosurgery (SRS)
Radiation: Whole-Brain Radiation Therapy (WBRT)

First Posted Date: 2012-10-10

Last Posted Date: 2024-03-15

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 17

Registration Number: NCT01703507

Locations: 🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Donor Stem Cell Boost in Treating Patients With Low Blood Cells After Donor Stem Cell Transplant

Not Applicable

Withdrawn

Conditions: Lymphopenia
Anemia
Thrombocytopenia
Hematopoietic/Lymphoid Cancer
Neutropenia

Interventions: Biological: Allogeneic hematopoietic stem cell transplantation
Biological: Peripheral blood stem cell transplantation
Procedure: Management of therapy complications

First Posted Date: 2012-08-08

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT01660347

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

Phase 1

Active, not recruiting

Conditions: Prostate Cancer
Recurrent Prostate Cancer
Stage IIA Prostate Cancer
Stage IIB Prostate Cancer
Adenocarcinoma of the Prostate

Interventions: Radiation: Brachytherapy
Radiation: Stereotactic Body Radiation Therapy
Procedure: Quality-of-life assessment
Other: Questionnaire administration

First Posted Date: 2012-08-02

Last Posted Date: 2024-05-03

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 42

Registration Number: NCT01655836

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Pilot Immunotherapy Trial for Recurrent Malignant Gliomas

Phase 1

Completed

Conditions: Malignant Glioma of Brain

Interventions: Drug: IGF-1R/AS ODN
Device: biodiffusion chamber

First Posted Date: 2012-03-12

Last Posted Date: 2018-06-20

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 13

Registration Number: NCT01550523

Locations: 🇺🇸
Thomas Jefferson University Hospital; Jefferson Hospital for Neurosciences, Philadelphia, Pennsylvania, United States

A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

Phase 2

Terminated

Conditions: Hematologic Malignancy
Chronic Lymphocytic Leukemia
CLL
Leukemia
Lymphoma
Myeloma
Acute Myelogenous Leukemia
AML
ALL
Non-hodgkin's Lymphoma

Interventions: Radiation: Total Body Irradiation (TBI)
Biological: Donor Lymphocyte Infusion (DLI)
Drug: Cyclophosphamide (CY)
Drug: Tacrolimus
Drug: Mycophenolate Mofetil (MMF)
Biological: Hematopoietic Stem Cell Transplant (HSCT)

First Posted Date: 2012-02-14

Last Posted Date: 2016-11-29

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 4

Registration Number: NCT01532635

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver

Phase 2

Active, not recruiting

Conditions: Stage IV Uveal Melanoma

Interventions: Device: Sir-Spheres®

First Posted Date: 2011-11-17

Last Posted Date: 2022-12-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 48

Registration Number: NCT01473004

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy